tetano
Editor, Senior Moderator
Annu Rev Immunol. 2013 Jan 16. [Epub ahead of print]
Broadly Neutralizing Antiviral Antibodies.
Corti D, Lanzavecchia A.
Source
Institute for Research in Biomedicine (IRB), 6500 Bellinzona, Switzerland and Humabs BioMed SA, 6500 Bellinzona, Switzerland; email: davide.corti@irb.usi.ch.
Abstract
A fascinating aspect of viral evolution relates to the ability of viruses to escape the adaptive immune response. The widely held view has been that the great variability of viral glycoproteins would be an absolute obstacle to the development of antibody-based therapies or vaccines that could confer broad and long-lasting protection. In the past five years, new approaches have been developed to interrogate human memory B cells and plasma cells with high efficiency and to isolate several broadly neutralizing antiviral antibodies against highly variable pathogens such as HIV-1 and influenza virus. These antibodies not only provide new tools for prophylaxis and therapy for viral diseases but also identify conserved epitopes that may be used to design new vaccines capable of conferring broader protection. Expected final online publication date for the Annual Review of Immunology Volume 31 is March 19, 2013. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.
PMID:
23330954
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23330954
Broadly Neutralizing Antiviral Antibodies.
Corti D, Lanzavecchia A.
Source
Institute for Research in Biomedicine (IRB), 6500 Bellinzona, Switzerland and Humabs BioMed SA, 6500 Bellinzona, Switzerland; email: davide.corti@irb.usi.ch.
Abstract
A fascinating aspect of viral evolution relates to the ability of viruses to escape the adaptive immune response. The widely held view has been that the great variability of viral glycoproteins would be an absolute obstacle to the development of antibody-based therapies or vaccines that could confer broad and long-lasting protection. In the past five years, new approaches have been developed to interrogate human memory B cells and plasma cells with high efficiency and to isolate several broadly neutralizing antiviral antibodies against highly variable pathogens such as HIV-1 and influenza virus. These antibodies not only provide new tools for prophylaxis and therapy for viral diseases but also identify conserved epitopes that may be used to design new vaccines capable of conferring broader protection. Expected final online publication date for the Annual Review of Immunology Volume 31 is March 19, 2013. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.
PMID:
23330954
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23330954